Silver Book Fact

The NEI-sponsored Age-Related Eye Disease Study (AREDS) found that individuals at high risk of developing advanced stages of age-related macular degeneration (AMD) lowered their risk of disease progression by about 25% when treated with the AREDS nutritional formula (daily, high-dose combination of vitamins C,E, beta-carotene, and zinc).

Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS report no. 8. Arch Opthalmol. 2001; 119(10): 1417-36. http://archopht.jamanetwork.com/article.aspx?articleid=268224

Reference

Title
A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS report no. 8
Publication
Arch Opthalmol
Publication Date
2001
Authors
Age-Related Eye Disease Study Research Group
Volume & Issue
Volume 119, Issue 10
Pages
1417-36
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The ACCORD Eye Study found that intensive glycemia control–compared with standard blood sugar control–in high risk type 2 diabetics, decreased progression of diabetic retinopathy by around 1/3 over 4 years–from…  
  • DR Treatment Reduced Risk of Blindness
    Appropriate treatment can reduce the risk of blindness or moderate vision loss from DR by more than 90%.  
  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…  
  • Economics of DR Treatment
    Laser treatment plus a VEGF inhibitor achieved an incremental cost-effectiveness ratio of $12,410 per quality adjusted life year in patients with DME.  
  • The prevalence of age-related macular degeneration (AMD) in the 40 and older population has decreased from an estimated 9.4% from 1988 to 1994, to 6.5% for 2005 to 2008.